{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-097897","form_type":"8-K","ticker":"CLB","cik":"0001958086","company_name":"Core Laboratories Inc. /DE/","filed_at":"2025-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.695809+00:00","generated_at":"2026-05-18T03:42:07.290024+00:00","sec_items":["1.01","2.02","2.03","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Core Lab Q2 rev $130.2M (+5% seq, flat YoY); ex-items EPS $0.19; free cash flow $10.4M","bullets":["Q2 revenue $130.2M (+5% sequentially, flat YoY); GAAP EPS $0.22; ex-items EPS $0.19 (-14% YoY, +33% sequentially).","Ex-items operating income $14.5M, margins 11% (+160 bps seq); incremental margins 41%.","Free cash flow $10.4M (+160% seq); net debt reduced $9.1M; leverage ratio improved to 1.27x.","Company repurchased 237,632 shares for $2.7M in Q2.","Credit facility amended: commitments raised to $150M from $135M, maturity extended to July 2029, $50M accordion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-097897","json":"https://secwatch.observer/filing/0000950170-25-097897.json","markdown":"https://secwatch.observer/filing/0000950170-25-097897.md","text":"https://secwatch.observer/filing/0000950170-25-097897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958086/000095017025097897/0000950170-25-097897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958086/000095017025097897/clb-20250722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T03:42:07.290024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}